Loading patent…
AssigneesYissum Research Development Company of the Hebrew University of Jerusalem, DIAB R&d 1, Bar-IIan University
InventorsShlomo Sasson, Erol Cerasi, Arie Lev Gruzman, Ella Meltzer-Mats
Estimating the term…
The present invention is directed to compounds such as: formula wherein linker is independently selected from the group consisting of —S—, —S—S—, —S—(CH2)n—, —NH—, —NH—(CH2)n—, —O—, —S02-, arylene, heteroarylene; R1 is selected from the group consisting of straight or branched C4-C20 alkyl, straight or branched C4-C20 alkenyl, straight or branched C4-C20 alkynyl, each optionally interrupted with at least one NH, C5-C7 saturated cycloalkyl or heteroalkyl ring, C5-C12 aromatic or heteroaromatic ring, each optionally substituted with at least one group selected from —COOH, —NH2, C1-C8 alkoxy, C1-C5 amidyle, C1-C5 carboxyl, halogen; and R2 is independently selected from the group consisting of H, OH, SH, NH2, NO2, halogen, CN, C1-C8 alkoxy, C1-C5 carboxylic acid, straight or branched C1-C8 alkyl, straight or branched C2-C10 alkenyl, straight or branched C2-C12 alkynyl each optionally substituted by at least one substituent selected from the group consisting of C1-C5 alkoxy, C1-C5 carboxylic acid, OH, SH, NH2, halogen; and compositions for use in the treatment of diabetes and related disorders.
1-32. (canceled)
A compound having the general formula (II):
A method of treating or preventing at least one condition selected from hyperglycemia, diabetes, altered insulin secretion, insulin resistance, cardiovascular disorder, obesity and metabolic syndrome X in a subject in need thereof, said method comprising administering to said subject compound of general formula (IV):
Dependencies are inferred from the claim text.